In today’s briefing:
- Giant Biogene IPO: Strong Growth Prospects Offsets Short-Term Margin Concerns
- Yunsung F&C IPO Preview
Giant Biogene IPO: Strong Growth Prospects Offsets Short-Term Margin Concerns
- Giant Biogene Holding (GBH HK) designs, develops and manufactures professional skin treatment products with recombinant collagen as the key bioactive ingredient in China.
- The company has filed for an IPO on the Hong Kong Stock Exchange and plans to raise proceeds of around HK$500m.
- We remain positive on Biogene’s growth prospects as it operates in a growing market which should further benefit from regulatory tailwinds.
Yunsung F&C IPO Preview
- Yunsung F&C is a leading maker of materials mixing equipment that are used in the rechargeable battery production.
- The IPO price range is from 53,000 won to 62,000 won and offering amount is from 106 billion won to 124 billion won. The book building starts on 26 October.
- According to the bankers’ valuation, the expected IPO market cap range is from 423 billion won to 495 billion won.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
